Philadelphia Business Journal – QR Pharma to start trial on Alzheimer’s drug – February 10, 2010
Philadelphia Business Journal – QR Pharma to start trial on Alzheimer’s drug – February 10, 2010
News Articles
News Articles
Philadelphia Business Journal – Maccecchini back in CEO seat at QR Pharma – November 28, 2008
Philadelphia Business Journal – Maccecchini back in CEO seat at QR Pharma – November 28, 2008 Article >>>>>
Press Release
Peter Davies, the 2015 Recipient of the Potamkin Award, Joins the Scientific Advisory Board of QR Pharma
Berwyn, PA, April 30, 2015: QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced the election of Dr. Peter Davies to its Scientific Advisory Board. This appointment follows the recent Series A funding. “We are thrilled to have Peter on our Scientific
News Articles, Press Release
We Need Volunteers to Test Novel Approaches and Help Cure Alzheimer’s Disease
By Dr. James Brewer An estimated 4.7 million Americans aged 65 and older have Alzheimer’s disease, and this number is projected to climb to 13.8 million by 2050. As astounding as these numbers are, the earliest phases of the illness are not captured and are believed to be even more prevalent. With so many in
News Articles
WallStreet Journal – Serial Entrepreneur to Receive Award – November 1, 2011
WallStreet Journal – Serial Entrepreneur to Receive Award – November 1, 2011 Article >>>>>
News Articles
U.S. 1 – Has Alzheimer’s Disease Met Its Match? – May 5, 2010
U.S. 1 – Has Alzheimer’s Disease Met Its Match? – May 5, 2010 Article >>>>>
Press Release
TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma
LA JOLLA, CA, November 18, 2008 – TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has licensed to QR Pharma, Inc. the worldwide rights to phenserine, Posiphen® and bisnorcymcerine. QR Pharma is an emerging biotechnology company focusing on the development of compounds to treat Alzheimer’s disease and other cognitive disorders. “We are pleased to
Press Release
QR Pharma to Present at the Alzheimer’s Association International Conference
Berwyn, PA, July 10, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting research data on its lead compound Posiphen® at the Alzheimer’s
Scientific Presentations
The Michael J. Fox Foundation for Parkinson’s Research: Therapeutics Development Initiative
Presentation, June 2008. More >>>>>
Press Release
QR Pharma to Present at 11th Annual World Pharma Congress
Berwyn, PA, May 29, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, QR’s chief executive officer, will speak at Cambridge Healthtech Institute’s 11th Annual World Pharma Congress,